SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
No Thumbnail Available
Identifiers
Date
2021-05-08
Authors
Ciruelos, E. M.
Garcia, A. A.
Cortes, J.
Pernas Simon, S.
Garate, E.
Mele, M.
Montano, A.
Martinez-Janez, N.
Oliveira, M.
de la Haba-Rodriguez, J.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
